Response to Shao Et Al.

Seeto, Alexander H.; Abrahamsen, Bo; Ebeling, Peter R.; Rodríguez, Alexander J.

doi:10.1002/jbmr.4224

Cited by 1 publication

(2 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Frontiers in Pharmacology frontiersin.org postmenopausal women (Seeto et al, 2021). Reasons for such discrepancy might be that different trials have different inclusion criteria for defining CVD and that not many trials used each specific cardiovascular event as the primary outcome.…”

Section: Figurementioning

confidence: 99%

“…Cohort studies also showed that bisphosphonates were associated with a decreased risk of myocardial infarction (Kang et al, 2012;Vestergaard, 2012;Kang et al, 2013;Wolfe et al, 2013). On the other hand, a meta-analysis indicated a higher risk of CVD comparing denosumab to bisphosphonates in postmenopausal women (Seeto et al, 2021). Findings from other meta-analyses indicated that this might be because denosumab has no impact on cardiovascular risks (Ferrieres et al, 2020;Lv et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case–control study

Tsai,

Sung,

Muo

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Purpose: Patients with osteoporosis are at an increased risk of cardiovascular disease (CVD). Several antiosteoporosis medications have been demonstrated with the benefit of preventing osteoporosis. Our aim is to assess the CVD risks associated with antiosteoporosis medications using the National Health Insurance Research Database in Taiwan between 2000 and 2016.Methods: Among 41,102 patients of 40+ years old with newly diagnosed osteoporosis, 69.1% (N = 28,387) of patients were included in the user cohort of antiosteoporosis medicines, of whom 13, 472 developed CVD by the end of 2016, while 14,915 did not. Using the nested case–control analysis in the user cohort (88.0% women and 77.4% elderly), we applied conditional logistic regression to estimate odds ratios (ORs) of eight types of CVD for the users of denosumab, bisphosphonate, teriparatide, and hormone replacement therapy (HRT).Results: The adjusted ORs of overall CVDs were 0.13 (95% CI: 0.12–0.15) for denosumab users, 0.52 (95% CI: 0.45–0.61) for teriparatide users, and 0.80 (95% CI: 0.76–0.85) for bisphosphonate users. The HRT users were at higher odds of coronary artery and peripheral artery diseases, heart failure, pulmonary embolism, and deep vein thrombosis.Conclusion: Denosumab, teriparatide, and bisphosphonate may have more protective effects against CVD than hormone therapy. Physicians may take subsequent cardiovascular risks into account when choosing an adequate antiosteoporosis medication for patients with osteoporosis.

show abstract

Section: Figurementioning

confidence: 99%